Review
Copyright ©The Author(s) 2016.
World J Gastroenterol. Sep 7, 2016; 22(33): 7440-7452
Published online Sep 7, 2016. doi: 10.3748/wjg.v22.i33.7440
Table 2 Problems of each combination therapy
TreatmentDiseasePhaseClinical trial numberStatus
Checkpoint inhibitor plus cytotoxic agents
Ipilimumab (anti-CDLA-4)PC1NCT01473940Ongoing
Gemcitabine
Nivolumab (anti-PD-1)PC1NCT02309177Ongoing
Nab-PTX ± gemcitabine
Combination with checkpoint inhibitors
Nivolumab (anti-PD-1)TNBC, GC, PC,1, 2NCT01928394Ongoing
Ipilimumab (anti-CTLA-4)SLCL. BC, OC
MEDI4736 (anti-PD-1)Solid tumor1NCT02261220Ongoing
Tremelimumab (anti-CTLA-4)
Nivolumab (anti-PD-1)Cervical cancer, BC, CRC, HN, GC, HCC, melanoma, NSCLC1, 2NCT01968109Ongoing
BMS-986016 (anti-LAG-3)
PDR001 (anti-PD-1)Solid tumors1, 2NCT02608268Ongoing
MBG453 (anti-TIM-3)
Ipilimumab (anti-CDLA-4)B7-H3 expressing tumors (melanoma, HN, NSCLC)1, 2NCT02381314Ongoing
MGA271 (anti-B7-H3)
Pembrolizumab (anti-PD-1)B7-H3 expressing tumors1, 2NCT02475213Ongoing
MGA271 (anti-B7-H3)(melanoma, HN, NSCLC)
Checkpoint inhibitor plus T cells stimulate agents
Nivolumab (anti-PD-1)Solid tumors, B-cell NHL1, 2NCT02253992Ongoing
Urelumab (anti-4-1 BB)
Pembrolizumab (anti-PD-1)Solid tumors1NCT02179918Ongoing
Urelumab (anti-4-1 BB)
Tremelimumab (anti-CTLA-4)Solid tumors1, 2NCT02205333Ongoing
MEDI6469 (anti-OX-40
MEDI4736 (anti-PD-L1)Solid tumors1, 2NCT02205333Ongoing
MEDI6469 (anti-OX-40)
Tremelimumab (anti-CTLA-4)Melanoma1NCT01103635Ongoing
CP-870,893 (anti-CD40)
Checkpoint inhibitor plus cancer vaccine
Ipilimumab (anti-CTLA-4) + GVAXPC2Ref 58Terminated
FOLFIRINOX followed byPC2NCT01896869Ongoing
Ipilimumab (anti-CTLA-4) + GVAX
Nivolumeb (anti-PD-1) + GVAXPC2NCT02243371Ongoing
Checkpoint inhibitor plus raditaion
Ipilimumab + radiationMelanoma1NCT01557114Terminated
Melanoma2NCT016899747Terminated
NSCLC2NCT0221739Ongoing
Melanoma2NCT01970527Ongoing